Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03485131
Other study ID # 1409
Secondary ID
Status Completed
Phase N/A
First received March 1, 2016
Last updated April 2, 2018
Start date April 2014
Est. completion date March 2018

Study information

Verified date March 2018
Source Manhattan Psychiatric Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a 4 week therapeutic pilot study with a 4 week follow-up period involving inpatients with treatment resistant DSM-IV schizophrenia or schizoaffective disorder diagnosis. Each eligible subject will receive either 20 minutes of active tDCS (transcranial direct-current stimulation) or sham stimulation twice a day on 5 consecutive weekdays for 4 weeks with a 4 week follow-up period.


Description:

The aim in this study is to conduct a pilot study on the efficacy of tDCS by assessing its efficacy in treatment refractory auditory verbal hallucinations in inpatients with chronic schizophrenia. Based on and expanding the findings by Brunelin et al. the hypothesis is that tDCS treatment with the cathode on the left temporal-parietal junction and the anode on the left dorsolateral prefrontal cortex can reduce the severity of auditory verbal hallucinations in patients with treatment refractory schizophrenia. The impact of tDCS on other schizophrenia symptoms in secondary exploratory outcome analyses together with the examination of the durability of an ameliorating effect will also be investigated.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date March 2018
Est. primary completion date July 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Inpatient adults (age 18-65 years) who meet diagnostic criteria for schizophrenia or schizoaffective disorder (using the Structured Clinical Interview for DSM)

- Auditory hallucinations without remission over 5 years (remission is defined as a period of 4 weeks without hallucinations) as documented in the patients' medical record

- Failure to respond to two previous adequate antipsychotic trials with adequate duration and adequate dosage

- Screening PANSS total rating of > 70

- PANSS hallucinatory behavior item > 4

- Capacity and willingness to sign informed consent

- On a stable antipsychotic regimen 4 weeks prior to screening and for the duration of the trial

- Normal hearing

- If female and not infertile, must agree to use one of the following forms of contraception for the duration of study participation: systemic hormonal treatment, an interuterine device (IUD) which was implanted at least 2 months prior to screening, or "double-barrier" contraception

- Willing to wear the tDCS device.

Exclusion Criteria:

- Prior history of seizure, other than that induced by Electro Convulsive Therapy

- Family history of seizures

- Significant unstable medical condition

- Pregnancy or women of childbearing capacity not using a medically accepted form of contraception when engaged in sexual intercourse

- Inability to provide informed consent

- Actively suicidal and or showing violent behavior

- Significant organic brain pathology by history and neurological examination, inclusive of history of head trauma, loss of consciousness for more than 5 minutes; intracranial metal implants, known structural brain lesion, devices that may be affected by transcranial Direct Current Stimulation (tDCS) (pacemaker, medication pump, cochlear implant, implanted brain stimulator)

- Active substance abuse

- Increased intracranial pressure, unstable cardiovascular disease, sleep apnea

- Individuals with a clinically defined neurological disorder

- Frequent and persistent migraines

- History of adverse reaction to neurostimulation or open skin wounds that would preclude safe placement of tDCS electrodes

- Current use of medications known to lower seizure threshold (serotonergic or tricyclic antidepressants)

- If pregnant or breast feeding at the time of screening

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Transcranial direct-current stimulation (tDCS)
Stimulation sessions will be conducted twice a day on 5 consecutive weekdays. The twice daily sessions will be separated by at least 3 hours (one in the morning and the other one in the PM). The duration of treatment will be 4 weeks
Placebo
Placebo/sham stimulation: After 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse is delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period

Locations

Country Name City State
United States Manhattan Psychiatric Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
Manhattan Psychiatric Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

Nitsche MA, Boggio PS, Fregni F, Pascual-Leone A. Treatment of depression with transcranial direct current stimulation (tDCS): a review. Exp Neurol. 2009 Sep;219(1):14-9. doi: 10.1016/j.expneurol.2009.03.038. Epub 2009 Apr 5. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction on the severity of auditory verbal hallucinations Reduction of Auditory Hallucinations Rating Scale (AHRS (12) items) 8 weeks
Secondary Impact of tDCS on other schizophrenia symptoms Reduction of scores in Positive and Negative Symptom Scale 8 weeks
Secondary Impact of tDCS on Clinical Global Impression Global Severity of Illness measure 8 weeks
Secondary Impact of tDCS on MATRICS MATRICS: Comprehensive assessment of cognitive functions 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A